Lilly Strattera "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's Aug. 12 "approvable" letter for Strattera (atomoxetine) requests data that will require "analyses from either existing studies or a potential new study" of the non-stimulant attention deficit hyperactivity disorder product, Lilly says. The firm "continues to plan for final FDA approval in the spring of 2003," although "approval timing is contingent upon further discussions with the FDA regarding the additional data requested
You may also be interested in...
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.